Surgery is the first choice in the management of grade 2 meningiomas. However, grade 2 meningiomas are a heterogeneous group of histologically aggressive tumors, with a high incidence of tumor recurrence and progression as compared to benign meningiomas. Therefore, treatment options for tumor recurrence and progression include repeat surgery and radiotherapy. Given the increased morbidity and poor quality of life after repeat surgical resection21, postoperative radiotherapy is advocated in the management of postoperative residual or recurrent grade 2 meningiomas.
Radiotherapy for grade 2 meningiomas
Although adjuvant radiotherapy for atypical meningiomas after gross total resection is still on controversial, it could significantly improve tumor control rate after subtotal resection22. Mair et al23 analyzed 114 cases of grade 2 atypical meningiomas diagnosed using 2000 WHO criteria, and reported a significant benefit after radiotherapy after subtotal resection. In the study of Jo K et al24, for atypical meningiomas with incomplete resection, the median interval to tumor recurrence increased from 17 months for surgery alone to 39 months for adjuvant radiotherapy.
SRS and fractionated external beam radiotherapy (fEBRT) are both reasonable options for postoperative residual or recurrent grade 2 meningiomas. Previous studies have reported SRS and fEBRT could offer a 3-year tumor control rate of 19%-74% 12–17and 45%-71% 12, 17, 25for grade 2 meningiomas respectively. However, studies did not find significant difference in tumor control between fEBRT and SRS17, 26. As SRS has the advantage of a highly precise, better dose conformity, minimizing radiation dose to surrounding tissues and shorter duration of treatments, it seems more attractive than fEBRT.
Tumor control after SRS and related risk factors
Tumor control after SRS and related risk factors have been reported in the literatures. In the study of Choi et al13, 25 cases of residual or recurrent atypical meningiomas treated with SRS with a median marginal dose of 22 Gy (range, 16–30) in 1 to 4 fractions, the 3-year local control rate was 74%, the number of recurrences before SRS, late SRS and age at treatment ≥ 60 years were associated with recurrence after SRS on univariate analysis. In the study of Ferraro et al27, 31 cases of atypical meningiomas were treated with GKRS, the median time to recurrence was 27.5 months, the 3-year PFS was 70.1%, margin dose was the only significant factor related with recurrence in multivariate analysis. In the study of Pollock et al14, 50 cases of grade 2 (= 37) and 3 (n = 13) treat with SRS with a median margin dose of 15 Gy. The 5-year PFS was 40%. In patients who failed prior EBRT, the 3-year PFS was 19%. Having failed EBRT was a negative predictor of PFS. In the study of Kano et al15, the authors found the 5-year PFS in lesions treated with SRS below 20 Gy and 20 Gy were 29.4% and 63.1% respectively. The marginal dose < 20 Gy was a significant factor for PFS in high-grade meningiomas treated with SRS. Aboukais et al16 reported 27 cases of grade 2 meningiomas treated with SRS with a median margin dose of 15.2 (range, 12–21) Gy, the 3-year local control was 40%. Age and tumor volume were significantly related with local tumor control in univariate analysis.
In the current study, because some tumors were close to optic chiasm and optic nerve or due to the large tumor volume, the median margin dose was 14.5 Gy and 13.5 Gy in secondary and de novo grade 2 meningioma group respectively, which might be a little lower than other studies. The radiological PFS was 74% and 55% at 2 and 3 years respectively, which was similar with other studies. The median time to radiological progression was shorter in secondary grade 2 meningioma group than de novo grade 2 meningioma group (31.4 vs 48.9 months), secondary grade 2 meningiomas were significantly related with poorer prognosis. Meningiomas with multiple recurrences and prior treatment failures are considered more aggressive and difficult to treat. However, in the current study, all of the secondary grade 2 meningiomas had at least twice surgery failures and GKRS treatment failure and were more aggressive and resistant to radiation than those de novo grade 2 meningiomas. Besides, there was no radiation-naïve patient in the secondary grade 2 meningioma group. Therefore, this could be a source of bias. Up to now, there was no standard treatment for secondary grade 2 meningiomas. Due to its poor prognosis, higher radiation dose might be helpful for better tumor control.
Secondary grade 2 meningiomas
Malignant transformation is not an uncommon phenomenon in benign meningiomas. It is estimated that 20%-40% of meningiomas are secondary tumors which originated from grade 1 meningiomas4–6. As stepwise genetic progression involving in malignant transformation3, 28, 29, secondary and de novo grade 2 meningiomas may behave differently. Recent studies indicated secondary meningiomas were associated with poor PFS and overall survival. In the study of Zhao et al18, 89 cases of atypical meningiomas were reviewed. Total resection was achieved in 80.9%. Forty (44.9%) patients underwent radiotherapy after surgery. Patients with secondary atypical meningiomas showed a threefold increased risk of recurrence. Secondary atypical meningiomas were related with poor PFS on multivariate analysis. In the study of Champeaux et al4, 194 patients with grade 2 meningiomas were reviewed. Thirty-one patients (16%) had a previous history of grade 1 meningiomas. These patients underwent a total of 344 surgical resections and 43.3% received radiotherapy. Secondary grade 2 meningiomas were related with the surgical recurrence-free survival and overall survival. In these studies, only a part of patients underwent radiotherapy for secondary meningiomas. There was no study comparing the outcomes between secondary and de novo grade 2 meningiomas undergoing GKRS.
In the current study, we did not investigate molecular markers in this study. CDKN2A/B and TERT promoter have been associated with meningioma behavior and poor prognosis30, 31. The 2021 WHO classification system indicates any meningioma with CDKN2A/B homozygous deletion and/or TERT promoter mutation is allotted to grade 3, irrespective of histological criteria of anaplasia8. Thus, future study needed to investigate molecular markers and genetic signatures associated with malignant transformation and prognosis.
Study limitations
Although this was the first study comparing outcomes between secondary and de novo grade 2 meningiomas undergoing GKRS, there were several limitations in the study. First, it was a single-center retrospective study with selection and treatment biases. Second, because of the rare incidence of secondary meningiomas, only 6 cases of secondary grade 2 meningiomas treated with GKRS were included in this study. The statistical power was limited by the number of cases in the study. Third, the pathological diagnosis was not based on the 2021 WHO classification system. The information of molecular markers was not available in this study. Finally, there was no radiation-naïve patient in the secondary grade 2 meningioma group. This could be a source of bias.